Tarafenacin (SVT40776) is a novel and potent M3 muscarinic receptor antagonist being developed for the treatment of overactive bladder. SVT-40776 shows highly selective for M(3) over M(2) receptors (Ki = 0.19 nmol.L(-1) for M(3) receptor affinity). SVT-40776 is a potent inhibitor of M(3) receptor-related detrusor contractile activity. The absence of effects on isolated atria preparations represents an interesting characteristic and suggests that SVT-40776 may lack unwanted cardiac effects; a feature especially relevant in a compound intended to treat mainly elderly patients.

纯度：≥98%

CAS：385367-47-5